ClinicalTrials.Veeva

Menu

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status

Conditions

HIV Infection

Treatments

Drug: Efavirenz

Study type

Expanded Access

Funder types

Industry

Identifiers

NCT00162227
AI266-913

Details and patient eligibility

About

This study is being conducted to assess the safety and tolerability of an oral liquid solution of Sustiva for antiretroviral therapy-naive or therapy-experienced HIV-1 infected children between the ages 3-16 who are failing or intolerant of current antiretroviral regimen and who are unable to swallow Sustiva capsules.

Sex

All

Ages

3 to 16 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Children 3-16 years of age
  • Anti-retroviral naive or experienced
  • Failing or intolerant to current Anti-retroviral regimen
  • Limited available viable therapeutic options
  • Inability to take capsules/tablets

Exclusion criteria

  • Less than 10kg
  • Failure on or concomitant use of other NNRTIs
  • An active AIDS-defining opportunistic infection or disease
  • More than two episodes of moderate to severe diarrhea or vomiting lasting more than four days within the past three months

Trial contacts and locations

29

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems